Lipocine Inc. (LPCN) News
Filter LPCN News Items
LPCN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LPCN News Highlights
- For LPCN, its 30 day story count is now at 3.
- Over the past 6 days, the trend for LPCN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- CNS and PAR are the most mentioned tickers in articles about LPCN.
Latest LPCN News From Around the Web
Below are the latest news stories about LIPOCINE INC that investors may wish to consider to help them evaluate LPCN as an investment opportunity.
LPCN: 2022 Operational & Financial UpdateBy John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2022 was an eventful year for Lipocine Inc (NASDAQ:LPCN) with both product and strategy achievements. The company’s first developed product, Tlando, launched in 2022 following a March 2022 FDA approval. Other material events in the year include the shift in strategy to focus on the development of treatments for central |
Lipocine Announces Financial Results for the Year Ended December 31, 2022Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the year ended December 31, 2022 and provided a corporate update. |
Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common StockLipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on March 24, 2023. The shares of Series B Preferred Stock will be distributed to such recipients at 5:00 p.m |
Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Lipocine (NASDAQ:LPCN) has had a great run on the share market with its stock up by a significant 31% over the last... |
Lipocine to Present at Biotech ShowcaseLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced that its management will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events will take place January 9-11, 2023, in San Francisco, California. |
Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated CirrhosisLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced that it has completed enrollment in its Phase 2 proof-of-concept ("POC") study evaluating the therapeutic potential of LPCN 1148 for the management of decompensated cirrhosis of various etiologies. Lipocine intends to explore partnering LPCN 1148. |
LPCN: Focus on CNS DisordersBy John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Third Quarter 2022 Financial and Operational Results On November 9, 2022 Lipocine (NASDAQ:LPCN) filed its third quarter 2022 Form 10-Q and posted its earnings release for the quarter ending September 30, 2022. In addition to the events listed below, the company attended several investor and scientific conferences since our |
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update. |
Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused PipelineLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiated products, today announced George Nomikos, M.D., Ph.D., has joined Lipocine as Chief Medical Officer and Spyros Papapetropoulos, M.D. Ph.D., has been appointed Lead Director and Chairman of the Board. |
Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor ConferenceLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on treating CNS disorders, announced today that it will present at the H.C. Wainwright 6th Annual NASH Investor Conference to be held virtually on October 17. |